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CASE PRESENTATION
Patient 1: A 16-year-old woman was admitted owing to
an acute onset of both lower extremity paralysis lasting
for 5 h. Her past medical history and family history were
unremarkable. She denied taking herbal medicine,
diuretics, or laxatives. She appeared ill-looking and her
blood pressure was 110/80 mm Hg. Neurologic examination
revealed impaired sensation and decreased motor power,
grade 1/5 in both lower extremities, and grade 3/5 in both
upper extremities. The rest of the physical examination
was normal. Initial laboratory findings revealed
hypokalemic metabolic alkalosis, hypomagnesemia, and
hypocalciuria (Table 2).
Patient 2: A 24-year-old woman was admitted because
of cramps and paralysis of four extremities for 2 h,
preceded by a dry cough, fever, and myalgia, which began
1 day before admission. Her past medical history and
family history were unremarkable. She denied taking
herbal medicine, diuretics, or laxatives. Her blood pressure
was 110/70 mm Hg. Neurologic examination revealed
grade 0–1/5 motor power and impaired sensation were
detected in all four extremities. Initial laboratory findings
revealed hypokalemic metabolic alkalosis, hypomagnesemia,
and hypocalciuria (Table 2).
The clinical presentations and initial laboratory data of
the above patients are summarized in Tables 1 and 2.
DIAGNOSIS
Hypokalemic metabolic alkalosis with hypomagnesemia and
hypocalciuria presenting with acute paralysis and paresthe-
sias.
CLINICAL FOLLOW-UP
All symptoms and abnormal neurologic signs disappeared
after correction of hypokalemia and hypomagnesemia in
both patients. Initially, potassium and magnesium were
administered intravenously and was switched to per oral after
improvement of neurologic signs. Symptoms suggesting
upper respiratory viral infection in Patient 2 improved after
symptomatic supportive treatment. We performed renal
clearance study, gene analysis, and immunohistochemistry
of sodium–chloride cotransporter (NCC) in renal tissues to
elucidate the pathophysiologic cause. Informed consents were
obtained from both patients, and the study protocol was
approved by the Institutional Review Board of Seoul National
University Hospital.
As described elsewhere,1,2 renal clearance study using
diuretics was carried out. After overnight fasting, the patients
drank water (20 ml/kg of body weight) over 20 min and
received intravenous infusion of 0.45% saline at a rate of
40 ml/h. Urine output was measured every 20 min followed
by additional water intake (urine volume plus 20 ml/20 min).
When urine flow reached a maximal level, samples of blood
and urine were obtained to calculate basal values of free water
clearance, chloride clearance, and distal fractional chloride
reabsorption. For thiazide loading test, 100 mg of hydro-
chlorothiazide was orally administered to the patients. Water
loading was carried out as described above. For furosemide
loading test, 40 mg of furosemide was given intravenously to
the patients. In both tests, clearance data were obtained when
urine flow was maximal. Distal fractional chloride reabsorp-
tion was calculated using the following formula: CH2O/
(CH2OþCCl).
For the SLC12A3 gene analysis, both RNA and genomic
DNA (gDNA) were isolated from peripheral blood cells.
RNA were reversely transcribed (RT) to cDNA, and four
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overlapping cDNA fragments covering most of the coding
sequences of the SLC12A3 gene were amplified by nested
polymerase chain reactions and directly sequenced. Muta-
tions detected by the nested reverse transcription-polymerase
chain reaction were also confirmed by direct sequencing of
the polymerase chain reaction product of the corresponding
exon from gDNA.
Renal biopsy tissues from both patients were examined by
immunohistochemistry for thiazide-sensitive NCC and were
compared with those from the patient with nonspecific
chronic tubulointerstitial nephritis as control. The renal
tissues from the patients and control were fixed, dehydrated
and dewaxed, and treated with methanolic H2O2. After
treatment for permeabilization, the sections were incubated
overnight at 41C with rabbit polyclonal antibodies to the
human NCC,3 type 2 sodium–potassium–chloride cotrans-
porter (NKCC2).4 Thereafter, the sections were rinsed with
phosphate-buffered saline and incubated in biotinylated goat
anti-rabbit immunoglobulin G (BA-1000; Vector Laboratory,
Burlingame, CA, USA) for 30 min at room temperature.
Hematoxylin staining was used for counterstaining.
In renal clearance study, chloride clearance was markedly
increased and distal fractional chloride reabsorption was
remarkably decreased after furosemide loading in both
patients (Table 3). However, these two parameters of renal
clearance were not significantly affected by hydrochlorothia-
zide administration. These different responses to thiazide and
furosemide are compatible with the functional diagnosis of
Gitelman’s syndrome.1,2
Gene analysis revealed homozygous mutation at 967 TCC
codon in exon 25, which converts serine to phenylalanine
(S967F) in Patient 1 (Figure 1). In Patient 2, compound
heterozygous mutations at 839 GAT codon in exon 21 and
979 ATA codon in exon 26, which convert aspartate to
asparagine and isoleucine to threonine, respectively (D839N/
I979T), were found (Figure 2).
In control, NCC immunohistochemistry showed distinct
labeling along the apical membrane of the distal convoluted
Table 1 | Clinical presentation of the patients
Patient 1 Patient 2
Age (years) 16 24
Gender Female Female
Chief complaint Lower extremities
paralysis
Cramp and four
extremities paralysis
Blood pressure
(mm Hg)
110/80 110/70
Motor power Grade 1/5 in both lower
extremities and 3/5 in
both upper extremities
Grade 0–1/5 in all
four extremities
Table 2 | Laboratory data of the patients
Patient 1 Patient 2
Reference
values
Serum electrolytes
Na+ (mmol/l) 135 135 135–145
K+ (mmol/l) 2.8 1.9 3.5–5.5
Cl (mmol/l) 93 94 98–110
Mg2+ (mmol/l) 0.7 0.55 0.75–1.25
HCO3
 (mmol/l) 30 30.4 21–29
Ca2+ (mmol/l) 2.67 2.45 2.2–2.62
Plasma renin activity (ng/ml/h) 32.8 14.7 1–2.5
Serum aldosterone level (pg/ml) 403 147 50–194
Plasma pH 7.42 7.54 7.38–7.46
Urine Ca2+ (mmol/day) 0.2 0.35 1.75-4.49
Urine Ca2+/Cr 0.008 0.013
Table 3 | Results of the renal clearance study using
furosemide and hydrochlorothiazide
Patient 1 Patient 2
Cl clearance (ml/min)
Basal 0.9 2.3
Furosemide loading 29.0 11.6
Thiazide loading 2.1 1.9
Distal fractional Cl reabsorption (%)
Basal 86.1 65.0
Furosemide loading 9.7 14.0
Thiazide loading 81.4 68.0
967 TCC(Ser)→TTC(Phe)
in exon 25, homozygote
in exon 19, homozygoteReverse complementary sequences
766 GAG(Glu)→GAT(Asp)
170 810 82
´
Figure 1 | Gene analysis result of Patient 1. The patient had
homozygous mutation at 967 TCC codon in exon 25, which converts
serine to phenylalanine (S967F).
110 20
40
839 GAT(Asp) → AAT(Asn)
in exon 21, heterozygote
979 ATA(IIe) → ACA(Thr)
in exon 26, heterozygote
766 GAG(Glu) → GAT(Asp) in
exon 19, homozygote, reverse
complementary sequence
Figure 2 | Gene analysis result of Patient 2. The patient had
compound heterozygous mutations at 839 GAT codon in exon 21
and 979 ATA codon in exon 26, which convert aspartate to
asparagine and isoleucine to threonine, respectively (D839N/I979T).
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tubule. However, renal tissues from Patient 1 were devoid of
intact NCC immunostaining in the distal convoluted tubule.
NCC immunostaining was absent in the apical membrane of
the distal convoluted tubule and only faint staining for NCC
immunoreactivity was observed in the cytoplasm of the distal
convoluted tubule cells (Figure 3c). No discernible NCC
immunostaining was present in the apical membrane of the
distal convoluted tubule in Patient 2 (Figure 3e). In contrast,
NKCC2 immunostaining was all preserved in the thick
ascending limb cells in both control and the patients
(Figure 3).
DISCUSSION
Two adult patients with Gitelman’s syndrome were described
above. Gitelman’s syndrome is an autosomal-recessive renal
tubular disorder characterized by hypokalemic metabolic
alkalosis, hypomagnesemia, and hypocalciuria (Figure 4).5
It is caused by inactivating mutations in the gene for the
NCC (thiazide-sensitive NCC) of the distal convoluted
tubule, called SLC12A3.6,7 Gitelman’s syndrome should be
suspected in patients with hypokalemia, metabolic alkalosis,
and hypocalciuria. Patients with Gitelman’s syndrome usually
are normotensive, which differentiate them from patients
with Liddle’s syndrome. Hypomagnesemia is an important
feature of typical Gitelman’s syndrome, but may be absent
in some patients. Therefore, hypomagnesemia is not crucial
for the diagnosis of Gitelman’s syndrome. Patients with
Gitelman’s syndrome present in adolescence or early adult-
hood, which differs from the earlier onset of Bartter’s
syndrome. Most patients with Gitelman’s syndrome are
asymptomatic or complain of mild intermittent cramps,
fatigue, muscle weakness, or irritability. However, severe
symptoms such as tetany and paralysis have been reported8
and phenotypic variations are not uncommon in Gitelman’s
syndrome.9 These phenotypic variations and the absence of
standard diagnostic method make the definite diagnosis of
Gitelman’s syndrome more difficult.
Our two patients complained of severe paralysis or cramp,
which is more suggestive of Bartter’s syndrome, although
their onset time and laboratory examination results were
compatible with Gitelman’s syndrome. Before renal biopsy,
diagnosis of Gitelman’s syndrome was based on clinical
features and supplemented by the renal clearance study using
diuretics and genotyping of SLC12A3 in both patients. We
performed immunohistochemistry of the renal tissues from
both Gitelman’s syndrome patients to investigate the
expression of intact NCC. Similar clinical features, including
laboratory abnormalities and results of the renal clearance
study, can be found in chronic abuse of diuretics,
surreptitious vomiting, and atypical Bartter’s syndrome.
Mutations of SLC12A3, which is responsible for Gitelman’s
syndrome, did not always result in functional defect of NCC
and typical symptoms, although many mutations and
polymorphisms were found in patients with Gitelman’s
syndrome.10–12 We tried to investigate whether there is a
correlation between the defect of NCC protein expression in
the renal tissues and the mutations of SLC12A3 in
symptomatic Gitelman’s syndrome patients.
Gitelman’s syndrome is linked to inactivating mutations in
the SLC12A3 gene, which encodes the NCC. To date, more
than 100 different mutations have been identified and when
mutant genes were introduced into Xenopus oocytes, loss of
NCC function, abnormal intracellular processing, and
absence of NCC from the cell membrane were all demon-
strated.13 Previous in vitro studies have shown that most of
point mutations lead to complete loss of expression and
cotransporter activity, whereas some of the missense muta-
tions in SLC12A3 exhibit partial function.14,15 In this study,
we demonstrated that in Gitelman’s syndrome, mutations in
the SLC12A3 gene are associated with defect of the intact
NCC expression on the apical membrane of distal convoluted
tubule. This finding seems to be relevant with some
molecular defects of the NCC in Gitelman’s syndrome
patients and suggests a correlation between clinical functional
defect and protein expression in the tissue level.
Our two patients had different mutation types: Patient 1
exhibited a classical homozygous pattern and Patient 2
revealed a compound heterozygous pattern. According to a
previous report,16 only 18% of the cases of Gitelman’s
syndrome exhibited homozygous mutations and about 45%
of all patients were compound heterozygotes. The second
most common type of mutation was from the heterozygous
patients. These differences in mutation may produce
phenotypic variations and may account for the variable
NCC protein expression in this immunohistochemical study.
Specifically, the absence of NCC immunoreactivity was
complete in the patient with compound heterozygous
mutation (Patient 2). Interestingly, the patient with homo-
zygous mutation (Patient 1) was devoid of intact NCC
immunostaining along the apical membrane of the distal
convoluted tubule, but showed a weak cytoplasmic immuno-
reactivity for NCC.
It has been proposed that NCC mutations can reduce or
abolish the transporter activity by five mechanisms: (1)
impairment of protein synthesis, (2) impairment of protein
processing, (3) interference with insertion of an otherwise
functional protein into plasma membrane, (4) modification
of functional properties of the cotransporter, and (5)
accelerated protein removal or degradation.17 Thus, it is
conceivable that complete absence of NCC immunostaining
seen in Patient 2 might be caused by impaired cotransporter
protein synthesis or accelerated protein degradation.
On the other hand, Patient 1 revealed a faint NCC
immunostaining, which was confined within the cytoplasm,
suggesting that impairment of cotransporter protein proces-
sing or insertion into apical plasma membrane might have a
role. This finding indicates that chaperone treatment might
be applied to the patients with Gitelman’s syndrome in the
future.18 Previously, it has been demonstrated that glycosy-
lation is essential for efficient function and surface expression
of the NCC protein19 and that several missense mutations
along the NCC were functionally inactive because of its
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Figure 3 | Immunohistochemistry of thiazide-sensitive NCC and NKCC2 in renal biopsy tissues from two patients with (c–f) Gitelman’s
syndrome and the (a and b) control. Whereas the NCC immunohistochemistry in the control showed a distinct labeling along the apical
membrane of the (a) DCT, the results of the renal tissues from the patients with Gitelman’s syndrome were devoid of (c and e, see the text
for details.) intact NCC immunostaining. In contrast, immunostaining for NKCC2 in the cortical TAL was all intact in both the control and
patients. DCT, distal convoluted tubule; TAL, thick ascending limb.
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defective glycosylation.15 Further studies are required to
answer the question whether interference with NCC glyco-
sylation or insertion into plasma membrane has a pathogenic
role in some patients with Gitelman’s syndrome.
The renal clearance study and genotyping, which were
used for diagnosis of Gitelman’s syndrome in our patients,
are the two methods available for differential diagnosis.
However, they have some limitations to be a standard
diagnostic method. The renal clearance study is very inconve-
nient and cumbersome. It may show confusing results
in patients with chronic abuse of diuretics, surreptitious
vomiting, or atypical Bartter’s syndrome, although the respo-
nses to thiazide and furosemide differ between Gitelman’s
syndrome and Bartter’s syndrome.1,2 It is also limited in
patients with azotemia, although renal function is nearly
always preserved in Gitelman’s syndrome.8 Genotyping is
known to be the best method for confirming the diagnosis,
but it is impractical owing to laboratory unavailability in
most hospitals.10–12 A vast number of different novel
mutations and polymorphisms of SLC12A3 in Gitelman’s
syndrome in addition to the impracticability makes geno-
typing difficult on a routine basis. Immunohistochemistry of
NCC in the renal tissues of patients may be a reliable
diagnostic method, but it is invasive and impractical in most
hospitals. Therefore, a simple, reliable diagnostic method
capable of detecting functional defect of NCC is needed. It
has also been shown that sodium transporters such as type 3
sodium–hydrogen exchanger, NKCC2, and NCC could be
detected in urine by immunoblotting,20 which may have
some potential in the diagnosis of Gitelman’s syndrome.
CLINICAL PERSPECTIVE AND CONCLUSIONS
Two patients with Gitelman’s syndrome who were described
above presented with severe symptoms, which are more com-
mon in Bartter’s syndrome. However, their laboratory features
and clearance studies were compatible with Gitelman’s
syndrome. We confirmed their mutations of SLC12A3 and
the defect of NCC expression in their renal tissues. It is the
first report that directly showed the defect of intact NCC in
the renal tissues of Gitelman’s syndrome patients. Although
immunohistochemistry of NCC is a method to ascertain the
defect of NCC expression, a new diagnostic method is needed
owing to its invasiveness and impracticability. Further study
is required to develop a new diagnostic method, which can
correlate functional defect with gene defect.
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SLC12A3 gene-inactivating mutation
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Figure 4 | Simplified pathophysiology of Gitelman’s syndrome.
Defect of NCC expression caused by SLC12A3 gene-inactivating
mutation results in hypokalemic metabolic alkalosis,
hypomagnesemia, and hypocalciuria.
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